Canadian Policy May Temper One Argument Against HHS IPI Plan

By John Wilkerson, Rachel Cohrs  
August 13, 2019 at 1:14 PM
Canada may have tempered an argument against the Trump administration’s international reference pricing plan when it removed the United States from the list of countries it references when setting drug prices. The argument is that HHS’ proposed International Pricing Index ties Medicare Part B drug prices to prices in countries that, in turn, reference drug prices in the United States, but it seems Canada was one of only two countries on the IPI reference-country list to reference U.S. drug prices...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.